Launch of Sales of Levonorgestrel Emergency Contraceptive Tablets
First written in FY2019-Q2. 3 of 4 entries say "Cited as achieved", first in FY2019-Q3. Latest entry: FY2021-Q1.
No other company in this theme has enough history to compare yet.
- FY2021-Q1Cited as achievedAnnual report
「For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
Levonorgestrel tablets, launched in March 2019, are again listed as a product targeted for market-share expansion in the obstetrics and gynecology field. - FY2020-Q2Cited as achievedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016, while seeking to expand the market share of generic products, principally Dienogest tablets, a treatment for endometriosis, and Levonorgestrel tablets, an emergency contraceptive.」
Levonorgestrel tablets are again listed as a product targeted for market-share expansion in the obstetrics and gynecology field, but no new milestone relating to the start of sales is provided. - FY2019-Q3Cited as achievedAnnual report
「In March 2019, we commenced sales of Levonorgestrel tablets, a generic emergency contraceptive. Going forward, we will continue to contribute to improving the quality of life of more patients by expanding our product portfolio in obstetrics and gynecology.」
Reiterates the launch of levonorgestrel tablets in March 2019 as a past achievement and continues the policy of expanding the product lineup in the obstetrics and gynecology fields. - FY2019-Q2First statedAnnual report
「In March 2019, we commenced sales of Levonorgestrel tablets, a generic emergency contraceptive. Going forward, we will continue to contribute to improving the quality of life of more patients by expanding our product portfolio in obstetrics and gynecology.」
Describes the specific product launch in March 2019 and its connection with expanding the product lineup in the obstetrics and gynecology fields and improving patients’ quality of life.